Achillion Pharmaceuticals, Inc.ACHN announced positive interim data from clinical studies evaluating its factor D inhibitors - ACH-4471, ACH-5228 and ACH-5548. Two phase II studies are evaluating the ...
RESEARCH TRIANGLE PARK, N.C., March 22, 2021 (GLOBE NEWSWIRE) -- BioCryst Pharmaceuticals, Inc. (Nasdaq: BCRX) today announced that its oral Factor D inhibitor, BCX9930, significantly increased ...
The first-in-class oral factor D inhibitor danicopan (Voydeya) has been approved for the management of extravascular hemolysis in patients with paroxysmal nocturnal hemoglobinuria (PNH). EVH affects ...
The complement system constitutes an effective first line of defense against invading pathogens. Its components recognize pathogenic cell surfaces and trigger cell lysis and inflammatory responses 1,2 ...
BioCryst Pharmaceuticals, Inc. (BCRX) has made great progress in advancing its pipeline. That's because it is currently evaluating the use of oral D Factor inhibitor, known as BCX10013, for the ...
For years, Alexion has been the only name in the game for a blood disease called paroxysmal nocturnal hemoglobinuria (PNH). Now, a number of Big Pharmas want in, vying to show their candidates can go ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback